Nilofabicin 是一种有效的烯酰-（酰基-载体-蛋白）还原酶下降（FabI）抑制剂，可用于治疗复杂急性疾病的研究。

Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.

Nilofabicin had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin. Among 203 strains of Staphylococcus aureus, the MICs of Nilofabicin were 0.06 to 1.0 μg/ml, with MIC(50) and MIC(90) values of 0.25 μg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 μg/ml)[3].

934628-27-0

C19H20N2O2S

340.44

CG0549;CG-0549;CG400549;CG 0549;CG-400549;CG 400549;Nilofabicin

DMSO:95 mg/mL (279.05 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years